移动医疗应用对 2 型糖尿病患者自我管理的影响：系统评价方案。
Impact of mobile health applications on self-management in patients with type 2 diabetes mellitus: protocol of a systematic review.
机构信息
Department of Primary Care & Public Health, School of Public Health, Imperial College London, London, UK.
Department of Public Health, Federal Ministry of Health, Abuja, Nigeria.
出版信息
BMJ Open. 2019 Jun 25;9(6):e025714. doi: 10.1136/bmjopen-2018-025714.
INTRODUCTION
The emergence of mobile health (mHealth) solutions, particularly mHealth applications (apps), has shown promise in self-management of chronic diseases including type 2 diabetes mellitus (T2DM). While majority of the previous systematic reviews have focused on the effectiveness of mHealth apps in improving treatment outcomes in patients with T2DM, there is a need to also understand how mHealth apps influence self-management of T2DM. This is crucial to ensure improvement in the design and use of mHealth apps for T2DM. This protocol describes how a systematic review will be conducted to determine in which way(s) mHealth apps might impact on self-management of T2DM.
METHODS
The following electronic databases will be searched from inception to April 2019: PubMed, MEDLINE, EMBASE, Global Health, PsycINFO, CINAHL, The Cochrane Central Register of Controlled Trials, Scopus, Web of Science, ProQuest Dissertations & Theses Global, Health Management Information Consortium database, Google Scholar and ClinicalTrials.gov. The Cochrane risk of bias tool will be used to assess methodological quality. The primary outcome measures to be assessed will be 'change in blood glucose'. The secondary outcomes measures will be 'changes in cardiovascular risk markers' (including blood pressure, body mass index and blood lipids), and self-management practices. Others will include: health-related quality of life, economic data, social support, harms (eg, death or complications leading to hospital admissions or emergency unit attendances), death from any cause, anxiety or depression and adverse events (eg, hypoglycaemic episodes).
ETHICS AND DISSEMINATION
This study will not involve the collection of primary data and will not require ethical approval. The review will be published in a peer-reviewed journal and a one-page summary of the findings will be shared with relevant organisations. Presentation of findings will be made at appropriate conferences.
TRIAL REGISTRATION NUMBER
CRD42017071106.
简介
移动医疗（mHealth）解决方案的出现，特别是 mHealth 应用程序（apps），在 2 型糖尿病（T2DM）等慢性病的自我管理方面显示出了巨大的潜力。虽然之前的大多数系统评价都集中在 mHealth 应用程序在改善 T2DM 患者治疗效果方面的有效性，但也需要了解 mHealth 应用程序如何影响 T2DM 的自我管理。这对于确保为 T2DM 设计和使用 mHealth 应用程序的改进至关重要。本方案描述了如何进行系统评价，以确定 mHealth 应用程序可能以何种方式影响 T2DM 的自我管理。
方法
将从创建至 2019 年 4 月，在以下电子数据库中进行检索：PubMed、MEDLINE、EMBASE、全球卫生、PsycINFO、CINAHL、Cochrane 对照试验中心注册库、Scopus、Web of Science、ProQuest 学位论文和全球学术研究库、健康管理信息联盟数据库、Google Scholar 和 ClinicalTrials.gov。将使用 Cochrane 偏倚风险工具评估方法学质量。主要结局指标将评估为“血糖变化”。次要结局指标将评估为“心血管风险标志物的变化”（包括血压、体重指数和血脂）以及自我管理实践。其他指标包括：健康相关生活质量、经济数据、社会支持、危害（例如，导致住院或急诊就诊的死亡或并发症）、任何原因导致的死亡、焦虑或抑郁以及不良事件（例如，低血糖发作）。
伦理和传播
本研究不涉及原始数据的收集，因此不需要伦理批准。审查将发表在同行评议的期刊上，并将相关组织分享发现的一页摘要。将在适当的会议上介绍研究结果。
注册号
CRD42017071106。
Zotero 插件